Preveceutical to begin clinical trials for sol-gel
Mr. Stephen Van Deventer reports
PREVECEUTICAL PREPARES FOR CLINICAL TRIALS FOR ITS SOL-GEL COVID-19 PROGRAM
Preveceutical Medical Inc. is preparing for clinical trials for its sol-gel COVID-19 program (see news release dated May 4, 2020).
Preveceutical believes that the cannabinoid sol-gel may reduce the possibility of contracting COVID-19 infections. To ensure that the COVID-19 sol-gel clinical program continues to rapidly progress, the company has retained Veristat, a global clinical research organization located in Massachusetts with operations around the world, including Canada, to assist with planning the clinical trial process and writing the required protocols.
Stephen Van Deventer, Preveceutical’s chief executive officer, commented: « Since the beginning of the pandemic, Preveceutical has mobilized its scientific understanding to investigate the development of treatments that could potentially reduce the transmission of COVID-19. We are very pleased with the progress of our COVID-19 sol-gel program and are committed to rapidly developing the clinical trial process. To support our efforts, we selected Veristat because of its extensive infectious disease experience and the substantial number of COVID-19-related clinical trials. »
Preveceutical is looking for an expedited pathway such as fast track or COVID-19 treatment acceleration program (CTAP).
Commercial terms of agreement
Under the terms of the consulting agreement, Veristat will provide services to design and develop Preveceutical’s COVID-19 sol-gel clinical program and write the required protocol.
The company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 at this time.
About Preveceutical Medical Inc.
Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products.